Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gout Flares Clear all
Completed Phase 2 Interventional Results available

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

NCT00927810
View directory record Official record
Conditions
Gouty Arthritis
Interventions
Canakinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Jul 22, 2026, 4:03 AM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

NCT07145229
View directory record Official record
Conditions
Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
Interventions
ABP-745 Dose A, ABP-745 Dose B, Colchicine, Placebo
Drug
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Peoria, Arizona • La Mesa, California • Norcross, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 22, 2026, 4:03 AM EDT
Recruiting Phase 4 Interventional

Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares

NCT07346079
View directory record Official record
Conditions
Gout Arthritis, Gout Flare, Gout
Interventions
Purified Cortophin Gel, 40 U, Purified Cortophin Gel 80 U
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

NCT06258213
View directory record Official record
Conditions
Gout, Acute Gout Flare, Gout Flares
Interventions
ABP-745, Placebo
Drug
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

NCT01356602
View directory record Official record
Conditions
Acute Gouty Arthritis
Interventions
Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
69
States / cities
Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Novel Methods for Ascertainment of Gout Flares -A Pilot Study

NCT02855437
View directory record Official record
Conditions
Gout
Interventions
IVR (Phone call), RheumPro (Smartphone application)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

NCT00829829
View directory record Official record
Conditions
Intercritical Gout
Interventions
Placebo, Rilonacept 80 mg, Rilonacept 160 mg
Other · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
67
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol

NCT01451645
View directory record Official record
Conditions
Intercritical Gout
Interventions
Colchicine (Colcrys®), placebo, allopurinol
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
37
States / cities
Alabaster, Alabama • Mesa, Arizona • Upland, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

NCT01080131
View directory record Official record
Conditions
Acute Gout
Interventions
Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
96
States / cities
Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

NCT02063997
View directory record Official record
Conditions
Gout
Interventions
Arhalofenate 600 mg, Allopurinol 300 mg, Colchicine 0.6 mg, Placebo, Arhalofenate 800 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
52
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

NCT01431638
View directory record Official record
Conditions
Acute Gouty Arthritis
Interventions
Canakinumab 150mg in prefilled syringe
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

NCT00819585
View directory record Official record
Conditions
Gout
Interventions
Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

NCT01470989
View directory record Official record
Conditions
Acute Gouty Arthritis Flares
Interventions
ACZ885, Triamcinolone acetonide 40 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Anniston, Alabama • Mobile, Alabama • Norwalk, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Not applicable Interventional

Evaluating the Effectiveness of a Chronic Disease Management Program for Gout

NCT01568879
View directory record Official record
Conditions
Recurrent or Tophaceous Gout
Interventions
Control, Gout Disease Management Program
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
21 Years to 80 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
All KPNC Facilities, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

NCT00798369
View directory record Official record
Conditions
Acute Gout
Interventions
Canakinumab, Triamcinolone acetonide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Anniston, Alabama • Birmingham, Alabama • Buena Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2012 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

NCT00856206
View directory record Official record
Conditions
Gout
Interventions
Rilonacept, Placebo
Biological · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
77
States / cities
Alabaster, Alabama • Mesa, Arizona • Burbank, California + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Jul 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

NCT00610363
View directory record Official record
Conditions
Gout
Interventions
Rilonacept, Placebo (for Rilonacept)
Biological · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
San Diego, California • Santa Maria, California • Whittier, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jul 22, 2026, 4:03 AM EDT
Terminated Phase 3 Interventional Results available

Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

NCT01459796
View directory record Official record
Conditions
Gout
Interventions
Rilonacept, Placebo, Allopurinol
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Jul 22, 2026, 4:03 AM EDT